Table 1 Clinical characteristics of the randomized patient groups
From: Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
| Characteristic | 977A | 977B | ||
|---|---|---|---|---|
| Number | % | Number | % | |
| Age at diagnosis (years) | ||||
| ≤ 40 | 89 | 9 | 80 | 8 |
| 41-50 | 197 | 20 | 207 | 21 |
| > 50 | 494 | 51 | 492 | 50 |
| unknown | 197 | 20 | 198 | 20 |
| Distant metastasis-free survival (years) | ||||
| no recurrence, < 5 | 617 | 63 | 648 | 66 |
| recurrence, < 5 | 198 | 20 | 184 | 19 |
| lost to follow-up, < 5 | 111 | 11 | 96 | 10 |
| no recurrence, 5-to 10 | 245 | 25 | 253 | 26 |
| recurrence, 5 to 10 | 51 | 5 | 49 | 5 |
| lost to follow-up, 5 to 10 | 357 | 37 | 395 | 40 |
| Estrogen receptor status | ||||
| positive | 657 | 67 | 686 | 70 |
| negative | 220 | 23 | 181 | 19 |
| unknown | 100 | 10 | 110 | 11 |
| Lymph node status | ||||
| negative | 749 | 77 | 749 | 77 |
| positive | 217 | 22 | 220 | 23 |
| unknown | 11 | 1 | 8 | 1 |
| Histologic grade | ||||
| well differentiated | 105 | 11 | 131 | 13 |
| moderately differentiated | 317 | 31 | 335 | 34 |
| poorly differentiated | 316 | 32 | 260 | 27 |
| unknown | 239 | 24 | 251 | 26 |
| Tumor size (cm) | ||||
| ≤ 2.0 | 482 | 49 | 505 | 52 |
| 2.1 to 5.0 | 363 | 37 | 356 | 36 |
| > 5.0 | 29 | 3 | 19 | 2 |
| unknown | 103 | 11 | 97 | 10 |
| Adjuvant treatment | ||||
| yes | 478 | 49 | 488 | 50 |
| no | 490 | 50 | 484 | 50 |
| tamoxifen monotherapy (ER+) | 318 | 33 | 332 | 34 |
| chemotherapy | 141 | 14 | 140 | 14 |
| unknown | 9 | 1 | 5 | 1 |
| Molecular subtypes | ||||
| Basal | 243 | 25 | 217 | 22 |
| HER2-E | 93 | 10 | 81 | 8 |
| Claudin-Low | 48 | 5 | 44 | 5 |
| Luminal A | 264 | 27 | 303 | 31 |
| Luminal B | 185 | 19 | 188 | 19 |
